NAMSW

NewAmsterdam Pharma Company N.V.

$12.65

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

—

Avg Volume

1,156

52W High

$30.45

52W Low

$11.37

Div. Yield

0.0%

Valuation

P/B Ratio

2.36

Margins

Gross Margin 100.0%

Operating Margin (1752.6%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(80.7%)

Return on Equity

(36.8%)

Return on Assets

(20.1%)

Liquidity & Leverage

Current Ratio

9.03

Quick Ratio

8.76

Debt / Equity

0.00

Total Cash

633.85M

Total Debt

82,000

About

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.